跳至主要内容
临床试验/NCT00211406
NCT00211406终止1 期

Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Manhattan Eye, Ear & Throat Hospital1 个研究点 分布在 1 个国家开始时间: 2005年9月21日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
终止
试验地点
1

研究概览

简要总结

The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control diabetic retinopathy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of patients with diabetic retinopathy.
  • Patients must be at least 18 years of age.
  • Visual acuity of 20/30 to 20/320 in study eye on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart
  • Visual acuity of 20/800 or better in fellow eye on the ETDRS visual acuity chart

排除标准

  • Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
  • Patients who have undergone intraocular surgery within the last 2 months.
  • Patient participating in any other investigational drug study.
  • Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication.
  • Inability to obtain photographs to document choroidal neovascularization (CNV) (including difficulty with venous access).
  • Patient with significant liver disease or uremia.
  • Patient with known adverse reaction to fluorescein and indocyanine green or iodine.
  • Patient has a history of any medical condition which would preclude scheduled visits or completion of study
  • Patient has had insertion of scleral buckle in the study eye
  • Patient has received radiation treatment
  • Patient is on anticoagulant therapy with the exception of aspirin
  • Patient is pregnant or nursing.

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验